| Authors: |
Tarantino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Lee D; Yale School of Medicine, New Haven, USA., Foldi J; University of Pittsburgh School of Medicine, Pittsburgh, USA., Soulos PR; Yale School of Medicine, New Haven, USA., Gross CP; Yale School of Medicine, New Haven, USA., Grinda T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA., Winer EP; Yale School of Medicine, New Haven, USA; Yale Cancer Center, Smilow Cancer Hospital, New Haven, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA., Krop IE; Yale School of Medicine, New Haven, USA; Yale Cancer Center, Smilow Cancer Hospital, New Haven, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA., Lustberg M; Yale School of Medicine, New Haven, USA; Yale Cancer Center, Smilow Cancer Hospital, New Haven, USA., Sammons S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: Sarahl_Sammons@dfci.harvard.edu. |
